GeNeuro is pursuing a novel approach for treating autoimmune diseases by seeking to block mechanisms suspected of participating to their onset and development. This approach is the result of 30 years of research into human endogenous retroviruses (HERVs), including 15 years within the Institut Mérieux group and INSERM, before GeNeuro was founded in 2006.